

Anti-hEGFR-hIgG4 (S228P)

Engineered human IgG4 monoclonal antibody against human EGFR

Catalog # hegfr-mab14

<http://www.invivogen.com/anti-hegfr-higg4s228p>

For research use only, not for diagnostic or therapeutic use

Version # 17K29-MM

PRODUCT INFORMATION

Content: 100 µg anti-hEGFR-hIgG4 (S228P), purified antibody, provided azide-free and lyophilized

Specificity: Epidermal growth factor receptor (EGFR)

Clonality: Monoclonal

Isotype: Human IgG4 (S228P)

Source: CHO cells

Formulation: 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.

Antibody resuspension

Add 1 ml of sterile water to obtain a concentration of 0.1 mg/ml.

Storage

- Product is shipped at room temperature. Store lyophilized antibody at -20°C. Lyophilized product is stable for at least 1 year.
- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding of anti-hEGFR-hIgG4 (S228P) to human EGFR has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hEGFR-hIgG4 (S228P) features the constant region of the human IgG4 (S228P) isotype and the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. EGFR is activated by binding specific ligands, including epidermal growth factor and transforming growth factor- α . Activation of EGFR promotes cell proliferation and survival, as well as angiogenesis, leading to tumor growth and metastasis. Binding of cetuximab to EGFR blocks ligand-receptor binding and induces receptor internalization and subsequent degradation. Consequently, cetuximab blocks downstream pathways which regulate cell growth and angiogenesis. In addition, cetuximab induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC)^{1,2}. Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck³.

Anti-hEGFR-hIgG4 (S228P) contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules.

Anti-hEGFR-hIgG4 (S228P) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

1. Kurai J. et al., 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 3(5):1552-61. 2. Kimura H. et al., 2007. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8):1275-80. 3. Vincenzi B. et al., 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 10(1):80-95.

ANTIBODY ISOTYPE FAMILY

For your research, InvivoGen provides an anti-hEGFR isotype family. This family consists of monoclonal antibodies comprising the variable region of cetuximab, and the constant region of three different human isotypes; IgG1, IgG4 and IgA2. The isotypes differ in their functional locations and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

Isotype	Description
Human IgG1	Most abundant IgG present in serum High CDC, high ADCC
Human IgG4	Least common IgG present in serum No CDC, low ADCC
Human IgA2	Major class in secretions, oligomeric forms, highly resistant to enzymatic degradation. No CDC, low ADCC

RELATED PRODUCTS

Product	Catalog Code
Anti-hEGFR-hIgG1 (Cetuximab)	hegfr-mab1
Anti-hEGFR-hIgA2	hegfr-mab7

Other antibody isotype families are available, such as Anti-hCD20, Anti-hPD1 and Anti- β -Gal(control).

For more information visit www.invivogen.com/antibody-isotypes

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

